NIKKEI 225
38,490.17 -347.29 (-0.89%) HANG SENG
18,424.96 -19.15 (-0.10%) CRUDE OIL
74.29 +1.04 (+1.42%) GOLD FUTURES
2,375.30 +27.90 (+1.19%) DOW
38,807.33 +96.04 (+0.25%) Bitcoin GBP
55,668.60 +531.55 (+0.96%)
BHVN Jul 2024 35.000 put
| Previous close | 3.8000 |
| Open | 4.2000 |
| Bid | 3.0000 |
| Ask | 4.2000 |
| Strike | 35.00 |
| Expiry date | 2024-07-19 |
| Day's range | 4.2000 - 4.2000 |
| Contract range | N/A |
| Volume | |
| Open interest | 96 |
PR NewswireBiohaven Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas including Immunology, Neuroscience, Metabolic Disorders and Oncology at Annual Investor R&D Day
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies, provides an overview of its development and regulatory advances across multiple therapeutic areas, and highlights the progress of its innovative degrader pipeline at the Company's 2024 Investor R&D Day today, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. Members of Biohaven's
PR NewswireBiohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate (ADC) BHV-1510 in Advanced or Metastatic Epithelial Tumors
Biohaven Ltd. (NYSE: BHVN) (Biohaven), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced the first patient has been dosed in a first-in-human Phase 1/2 study of BHV-1510, a highly differentiated Trophoblast Cell Surface Antigen-2 (Trop-2) directed Antibody Drug Conjugate (ADC), and the lead ADC program to advance into clinical trials in Biohaven's g
GuruFocus.comDirector Gregory Bailey Acquires 15,000 Shares of Biohaven Ltd (BHVN)
On May 13, 2024, Gregory Bailey, Director of Biohaven Ltd (NYSE:BHVN), purchased 15,000 shares of the company.
